| Name | Title | Contact Details |
|---|---|---|
Eric Stier |
Chief Legal Officer | Profile |
VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.
Drug Development Resources is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Highmark Delaware is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded by Walter Lorenz more than thirty years ago, Biomet Microfixation manufactures a complete range of craniomaxillofacial products, including LactoSorb, the first completely resorbable fixation system available in the U.S. Other products include
La Jolla Bioengineering Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.